Neena Patil Sells 1,200 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Neena Patil sold 1,200 shares of the stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total value of $278,196.00. Following the completion of the sale, the executive vice president owned 51,549 shares in the company, valued at approximately $11,950,604.67. The trade was a 2.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jazz Pharmaceuticals Stock Performance

JAZZ stock opened at $230.56 on Friday. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. The business’s fifty day simple moving average is $217.61 and its two-hundred day simple moving average is $188.84. Jazz Pharmaceuticals PLC has a twelve month low of $105.00 and a twelve month high of $243.32. The firm has a market cap of $14.48 billion, a price-to-earnings ratio of -11,522.24, a PEG ratio of 0.20 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The business had revenue of $1.07 billion for the quarter. Analysts predict that Jazz Pharmaceuticals PLC will post 22.09 earnings per share for the current year.

Jazz Pharmaceuticals News Summary

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Negative Sentiment: Jazz Pharmaceuticals said the Phase 3 LAGOON trial for Zepzelca did not meet its primary endpoint of overall survival in second-line small cell lung cancer. Jazz Pharmaceuticals Provides Update on Zepzelca (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
• Negative Sentiment: Reuters reported the trial failure could put Zepzelca’s current regulatory status at risk, raising uncertainty around a key oncology asset. Jazz Pharmaceuticals lung cancer drug fails main trial goal
• Negative Sentiment: Industry coverage from multiple outlets reinforced the setback, suggesting investor concern may persist until Jazz clarifies next steps for Zepzelca. Jazz Pharma announces late-stage trial setback for lung cancer therapy
• Negative Sentiment: FiercePharma noted the latest twist in the Zepzelca saga, highlighting the importance of the drug to Jazz’s cancer franchise and the market’s negative reaction to the failure. In latest twist in Zepzelca saga, Jazz and PharmaMar lung cancer drug fails phase 3 test
• Negative Sentiment: Separately, an SEC filing showed EVP Neena M. Patil sold 1,200 shares earlier this week, a small insider sale that may add to cautious sentiment. Jazz Pharmaceuticals PLC EVP Neena M. Patil sold shares
• Neutral Sentiment: Some recent commentary still frames Jazz as a value stock with a “moderate buy” analyst consensus, but this is being overshadowed by the trial disappointment. Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term

Analysts Set New Price Targets

A number of analysts have weighed in on JAZZ shares. UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the stock from $188.00 to $307.00 in a research note on Tuesday, May 19th. Weiss Ratings upgraded Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, May 26th. Leerink Partners raised their price target on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Bank of America raised their price target on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Piper Sandler raised their price target on Jazz Pharmaceuticals from $232.00 to $301.00 and gave the company an “overweight” rating in a research note on Friday, May 22nd. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $246.06.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Hilltop National Bank acquired a new stake in Jazz Pharmaceuticals in the fourth quarter worth about $36,000. LRI Investments LLC acquired a new stake in Jazz Pharmaceuticals in the fourth quarter worth about $38,000. Westpac Banking Corp acquired a new stake in Jazz Pharmaceuticals in the first quarter worth about $51,000. Leonteq Securities AG acquired a new stake in Jazz Pharmaceuticals in the fourth quarter worth about $50,000. Finally, Root Financial Partners LLC boosted its holdings in Jazz Pharmaceuticals by 42.8% in the first quarter. Root Financial Partners LLC now owns 297 shares of the specialty pharmaceutical company’s stock worth $56,000 after acquiring an additional 89 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.